TWI772296B - 穩定化的醣肽抗生素配方 - Google Patents

穩定化的醣肽抗生素配方 Download PDF

Info

Publication number
TWI772296B
TWI772296B TW106115255A TW106115255A TWI772296B TW I772296 B TWI772296 B TW I772296B TW 106115255 A TW106115255 A TW 106115255A TW 106115255 A TW106115255 A TW 106115255A TW I772296 B TWI772296 B TW I772296B
Authority
TW
Taiwan
Prior art keywords
vancomycin
sulfobutyl ether
alanine
pharmaceutical composition
acetyl
Prior art date
Application number
TW106115255A
Other languages
English (en)
Chinese (zh)
Other versions
TW201740955A (zh
Inventor
沙賓那 克澤爾
伊沃娜 傑史瑞卡
傑羅姆 李康夫
Original Assignee
丹麥商瑟利亞製藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 丹麥商瑟利亞製藥有限公司 filed Critical 丹麥商瑟利亞製藥有限公司
Publication of TW201740955A publication Critical patent/TW201740955A/zh
Application granted granted Critical
Publication of TWI772296B publication Critical patent/TWI772296B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW106115255A 2016-05-09 2017-05-09 穩定化的醣肽抗生素配方 TWI772296B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662333357P 2016-05-09 2016-05-09
US62/333,357 2016-05-09

Publications (2)

Publication Number Publication Date
TW201740955A TW201740955A (zh) 2017-12-01
TWI772296B true TWI772296B (zh) 2022-08-01

Family

ID=58745200

Family Applications (2)

Application Number Title Priority Date Filing Date
TW106115255A TWI772296B (zh) 2016-05-09 2017-05-09 穩定化的醣肽抗生素配方
TW110104598A TWI769694B (zh) 2016-05-09 2017-05-09 穩定化的醣肽抗生素配方

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW110104598A TWI769694B (zh) 2016-05-09 2017-05-09 穩定化的醣肽抗生素配方

Country Status (19)

Country Link
US (1) US10729708B2 (enExample)
EP (1) EP3454883A1 (enExample)
JP (1) JP6946343B2 (enExample)
KR (1) KR20190005940A (enExample)
CN (1) CN109069580A (enExample)
AR (1) AR109454A1 (enExample)
AU (1) AU2017262943B2 (enExample)
BR (1) BR112018072948A2 (enExample)
CL (1) CL2018003147A1 (enExample)
CO (1) CO2018011701A2 (enExample)
EA (1) EA201892413A1 (enExample)
IL (1) IL262796A (enExample)
JO (2) JOP20170111B1 (enExample)
MX (1) MX388732B (enExample)
SA (1) SA518400392B1 (enExample)
SG (1) SG11201809908TA (enExample)
TW (2) TWI772296B (enExample)
UY (1) UY37233A (enExample)
WO (1) WO2017194385A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6797795B2 (ja) 2014-11-06 2020-12-09 クセリア ファーマシューティカルズ エーピーエスＸｅｌｌｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ ＡｐＳ グリコペプチド組成物
WO2021231361A1 (en) * 2020-05-11 2021-11-18 Anovent Pharmaceutical (U.S.), Llc Pharmaceutical formulation containing active metabolites of remdesivir for inhalation
EP4192247A4 (en) * 2020-08-04 2025-01-08 Harrow IP, LLC Antibacterial compositions and methods for fabricating thereof
EP4014969A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
EP4014965A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
CN115804832A (zh) * 2021-09-14 2023-03-17 海南普利制药股份有限公司 一种万古霉素水溶液组合物
JPWO2023171588A1 (enExample) * 2022-03-08 2023-09-14
US20250295727A1 (en) * 2022-04-26 2025-09-25 Hikma Pharmaceuticals Usa Inc. Stable, ready-to-administer aqueous formulations of dalbavancin
GB202207344D0 (en) 2022-05-19 2022-07-06 Arecor Ltd Novel composition
GB202207345D0 (en) 2022-05-19 2022-07-06 Arecor Ltd Novel composition
CN117618338A (zh) * 2022-08-16 2024-03-01 海南普利制药股份有限公司 一种稳定的奥利万星药物水溶液及其制备方法
AU2023359652A1 (en) * 2022-10-12 2025-05-29 Hikma Pharmaceuticals Usa Inc. Liquid dalbavancin composition
WO2024079224A1 (en) * 2022-10-12 2024-04-18 Xellia Pharmaceuticals Aps Liquid dalbavancin composition
EP4431083A1 (en) * 2023-03-16 2024-09-18 Adalvo Limited Formulation of dalbavancin
WO2025158262A1 (en) * 2024-01-23 2025-07-31 Lupin Limited Stable pharmaceutical compositions of dalbavancin as ready-to-dilute formulation

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1278549A (en) * 1916-12-16 1918-09-10 J E Simmons Nut and bolt lock.
US4670258A (en) 1984-02-10 1987-06-02 Vanderbilt University Storable prepackaged aqueous solutions of vancomycin
US4885275A (en) 1987-10-15 1989-12-05 Eli Lilly And Company Vancomycin-HCL solutions and the lyophilization thereof
WO1997019690A1 (en) 1995-12-01 1997-06-05 Eli Lilly And Company Stable vancomycin hydrochloride solutions
JPH1180021A (ja) 1997-09-02 1999-03-23 Kayaku:Kk バンコマイシン注射剤
EP1276759B1 (en) * 2000-05-02 2008-07-30 Theravance, Inc. Reductive alkylation process on glycopeptides
ATE416791T1 (de) 2000-05-02 2008-12-15 Theravance Inc Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält
WO2001083520A2 (en) * 2000-05-02 2001-11-08 Theravance,Inc Polyacid glycopeptide derivatives
PL206492B1 (pl) * 2000-06-21 2010-08-31 Cubist Pharm Inc Kompozycja farmaceutyczna do doustnego dostarczania cefalosporyny i jej zastosowania
UA75083C2 (uk) 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US7119061B2 (en) * 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
BRPI0415637A (pt) 2003-10-31 2006-12-12 Univ Kansas derivados de sulfoalquil éter-alquil éter ciclodextrina
UA91208C2 (ru) 2005-02-14 2010-07-12 Венус Ремедиз Лимитед Фармацевтическая композиция, которая содержит антибактериальный гликопептид и цефалоспорин, для терапии резистентных инфекционных состояний
CN1857716A (zh) * 2006-03-14 2006-11-08 浙江大学 注射用盐酸万古霉素及其制备方法
JP2008201778A (ja) 2007-01-25 2008-09-04 Mochida Pharmaceut Co Ltd バンコマイシン液状製剤
US8518873B2 (en) 2007-09-12 2013-08-27 The Medicines Company Method of inhibiting clostridium difficile by administration of oritavancin
US7635773B2 (en) * 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
CN102755629A (zh) * 2012-08-02 2012-10-31 上海瑞创医药科技有限公司 与万古霉素形成抗菌增效包合物的组分和制备方法及其应用
US10124066B2 (en) 2012-11-29 2018-11-13 Insmed Incorporated Stabilized vancomycin formulations
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
WO2014194296A1 (en) 2013-05-30 2014-12-04 Scidose, Llc Formulations of vancomycin
JP6797795B2 (ja) * 2014-11-06 2020-12-09 クセリア ファーマシューティカルズ エーピーエスＸｅｌｌｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ ＡｐＳ グリコペプチド組成物
EP3302494A4 (en) 2016-01-08 2019-01-23 Gufic Biosciences Limited FREEZE-DRIED PARENTERAL COMPOSITION OF TIGECYCLIN AND METHOD FOR THE MANUFACTURE THEREOF
AU2017221435A1 (en) * 2016-02-18 2018-09-06 Melinta Therapeutics, Inc. Oritavancin formulations

Also Published As

Publication number Publication date
UY37233A (es) 2018-01-02
EP3454883A1 (en) 2019-03-20
JP2019518733A (ja) 2019-07-04
SA518400392B1 (ar) 2022-05-09
CA3021935A1 (en) 2017-11-16
SG11201809908TA (en) 2018-12-28
AU2017262943A1 (en) 2018-11-22
TW201740955A (zh) 2017-12-01
EA201892413A1 (ru) 2019-05-31
IL262796A (en) 2018-12-31
MX388732B (es) 2025-03-20
US20190175632A1 (en) 2019-06-13
CL2018003147A1 (es) 2018-12-28
TWI769694B (zh) 2022-07-01
AR109454A1 (es) 2018-12-12
KR20190005940A (ko) 2019-01-16
CO2018011701A2 (es) 2019-02-08
MX2018013584A (es) 2019-04-01
JOP20170111B1 (ar) 2022-03-14
US10729708B2 (en) 2020-08-04
JOP20220039A1 (ar) 2023-01-30
BR112018072948A2 (pt) 2019-02-19
CN109069580A (zh) 2018-12-21
TW202133875A (zh) 2021-09-16
JP6946343B2 (ja) 2021-10-06
AU2017262943B2 (en) 2020-05-14
WO2017194385A1 (en) 2017-11-16

Similar Documents

Publication Publication Date Title
TWI772296B (zh) 穩定化的醣肽抗生素配方
US12161690B2 (en) Glycopeptide compositions
CA3021935C (en) Stabilized glycopeptide antibiotic formulations
CA2964524C (en) Glycopeptide compositions